Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study

BACKGROUND/AIMS: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Ko...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Mol Hepatol
Main Authors: Cho, Byeong Wook, Kim, Seok Bae, Song, Il Han, Lee, Sae Hwan, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Kim, Seok Hyun, Lee, Byung Seok, Chae, Hee Bok
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Association for the Study of the Liver 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381834/
https://ncbi.nlm.nih.gov/pubmed/28297836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2016.0053
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados